000277342 001__ 277342
000277342 005__ 20240229155015.0
000277342 0247_ $$2doi$$a10.1002/ijc.34640
000277342 0247_ $$2pmid$$apmid:37403702
000277342 0247_ $$2ISSN$$a0020-7136
000277342 0247_ $$2ISSN$$a1097-0215
000277342 0247_ $$2altmetric$$aaltmetric:151048636
000277342 037__ $$aDKFZ-2023-01350
000277342 041__ $$aEnglish
000277342 082__ $$a610
000277342 1001_ $$00000-0002-4895-6728$$aRosas, Juan C$$b0$$eFirst author
000277342 245__ $$a(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer.
000277342 260__ $$aBognor Regis$$bWiley-Liss$$c2023
000277342 3367_ $$2DRIVER$$aarticle
000277342 3367_ $$2DataCite$$aOutput Types/Journal article
000277342 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1694183472_27132
000277342 3367_ $$2BibTeX$$aARTICLE
000277342 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277342 3367_ $$00$$2EndNote$$aJournal Article
000277342 500__ $$a#EA:C020# / 2023 Nov 1;153(9):1579-1591
000277342 520__ $$aFatigue is common in breast-cancer survivors. Our study assessed fatigue longitudinally in breast cancer patients receiving adjuvant radiotherapy (RT) and aimed to identify risk factors associated with long-term fatigue and underlying fatigue trajectories. Fatigue was measured in a prospective multicenter cohort (REQUITE) using the Multidimensional Fatigue Inventory (MFI-20) and analyzed using mixed models. Multivariable logistic models identified factors associated with fatigue dimensions at 2 years post-RT and latent class growth analysis identified individual fatigue trajectories. A total of 1443, 1302, 1203 and 1098 patients completed the MFI-20 at baseline, end of RT, after 1 and 2 years. Overall, levels of fatigue significantly increased from baseline to end of RT for all fatigue dimensions (P < .05) and returned to baseline levels after 2 years. A quarter of patients were assigned to latent trajectory high (23.7%) and moderate (24.8%) fatigue classes, while 46.3% and 5.2% to the low and decreasing fatigue classes, respectively. Factors associated with multiple fatigue dimensions at 2 years include age, BMI, global health status, insomnia, pain, dyspnea and depression. Fatigue present at baseline was consistently associated with all five MFI-20 fatigue dimensions (ORGeneralFatigue = 3.81, P < .001). From latent trajectory analysis, patients with a combination of factors such as pain, insomnia, depression, younger age and endocrine therapy had a particularly high risk of developing early and persistent high fatigue years after treatment. Our results confirmed the multidimensional nature of fatigue and will help clinicians identify breast cancer patients at higher risk of having persistent/late fatigue so that tailored interventions can be delivered.
000277342 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000277342 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277342 650_7 $$2Other$$abreast cancer
000277342 650_7 $$2Other$$adeterminants
000277342 650_7 $$2Other$$afatigue
000277342 650_7 $$2Other$$alongitudinal trajectories
000277342 650_7 $$2Other$$aradiotherapy
000277342 7001_ $$00000-0002-7822-6726$$aAguado-Barrera, Miguel E$$b1
000277342 7001_ $$aAzria, David$$b2
000277342 7001_ $$aBriers, Erik$$b3
000277342 7001_ $$aElliott, Rebecca$$b4
000277342 7001_ $$aFarcy-Jacquet, Marie-Pierre$$b5
000277342 7001_ $$aGiraldo, Alexandra$$b6
000277342 7001_ $$00000-0002-1711-6101$$aGutiérrez-Enríquez, Sara$$b7
000277342 7001_ $$aRancati, Tiziana$$b8
000277342 7001_ $$aRattay, Tim$$b9
000277342 7001_ $$aReyes, Victoria$$b10
000277342 7001_ $$aRosenstein, Barry$$b11
000277342 7001_ $$aDe Ruysscher, Dirk$$b12
000277342 7001_ $$aSperk, Elena$$b13
000277342 7001_ $$aStobart, Hilary$$b14
000277342 7001_ $$aTalbot, Christopher$$b15
000277342 7001_ $$aVega, Ana$$b16
000277342 7001_ $$aTaboada-Valladares, Begoña$$b17
000277342 7001_ $$aVeldeman, Liv$$b18
000277342 7001_ $$aWard, Tim$$b19
000277342 7001_ $$aWebb, Adam$$b20
000277342 7001_ $$aWest, Catharine$$b21
000277342 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b22$$udkfz
000277342 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b23$$udkfz
000277342 7001_ $$aConsortium, REQUITE$$b24$$eCollaboration Author
000277342 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.34640$$gp. ijc.34640$$n9$$p1579-1591$$tInternational journal of cancer$$v153$$x0020-7136$$y2023
000277342 909CO $$ooai:inrepo02.dkfz.de:277342$$pVDB
000277342 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-4895-6728$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000277342 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000277342 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000277342 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000277342 9141_ $$y2023
000277342 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-25$$wger
000277342 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-25
000277342 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
000277342 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
000277342 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000277342 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000277342 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000277342 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000277342 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000277342 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000277342 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000277342 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000277342 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000277342 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000277342 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000277342 980__ $$ajournal
000277342 980__ $$aVDB
000277342 980__ $$aI:(DE-He78)C020-20160331
000277342 980__ $$aUNRESTRICTED